



38 **ABSTRACT**

39 Researchers have developed multiple methods to characterize clinical and environmental  
40 strains of *Vibrio vulnificus*. The aim of our study was to use four assays to detect virulence  
41 factors in strains from infected patients and those from surface waters/sediments/oysters of  
42 South Carolina and the Gulf of Mexico. *Vibrio vulnificus* strains from clinical (n=81) and  
43 environmental (n=171) sources were tested using three real-time PCR methods designed to  
44 detect polymorphisms in the 16S rRNA, *vcg* and *pilF* genes and a phenotypic method, the ability  
45 to ferment D-mannitol. Although none of the tests correctly categorized all isolates, the  
46 differentiation between clinical and environmental isolates was similar for the *pilF*, *vcgC/E* and  
47 16S rRNA assays, with sensitivities of 74.1-79.2% and specificities of 77.4-82.7%. The *pilF* and  
48 *vcgC/E* assays are comparable in efficacy to the widely used 16S rRNA method, while the D-  
49 mannitol fermentation test is less discriminatory (sensitivity = 77.8%, specificity = 61.4%).  
50 Overall Percent Agreement for the D-mannitol fermentation method was also lower (66.7%)  
51 than Overall Percent Agreement for the 3 molecular assays (78.0% to 80.2%). This study  
52 demonstrated, using a large, diverse group of *Vibrio vulnificus* isolates, that three assays could  
53 be used to distinguish most clinical vs environmental isolates; however, additional assays are  
54 needed to increase accuracy.

55 **Key words:** *Vibrio vulnificus*, clinical, environmental, genotyping, virulence.

56 **1. INTRODUCTION**

57 *Vibrio vulnificus* is a halophilic, Gram negative bacterium, occurring naturally in coastal and brackish  
58 waters worldwide [1]. Primarily an opportunistic pathogen, *V. vulnificus* can cause skin infections  
59 through the exposure of open wounds to contaminated water, and is the leading cause of seafood-  
60 related deaths in the United States [2, 3]. Uncommon, but potentially deadly infections can occur from  
61 the consumption of raw shellfish, with onset of symptoms, including severe gastroenteritis and primary  
62 septicemia, within 24 hours. *Vibrio vulnificus* infections have a 50% or greater fatality rate, with greatest  
63 risk among immuno-compromised individuals, or persons with elevated serum iron, characteristic of  
64 liver disease [4].

65 While most frequently associated with filter-feeding oysters, *V. vulnificus* has also been detected in  
66 plankton, fish, eels, crabs, and lobsters [5]. Increases in environmental counts and human infections  
67 correlate well with warmer, summer temperatures [6-9], and a report citing significant increases in  
68 *Vibrio* spp., including *V. vulnificus*, infections from 1996-2010 is a cause for concern for public health  
69 officials [10]. More recent studies provide evidence that global increases in ocean water temperatures  
70 may generate conditions which allow *Vibrio* spp. and their accompanying diseases to proliferate in  
71 formerly less hospitable waters, exposing previously unaffected populations to increased health risks [6,  
72 11, 12].

73 Although *V. vulnificus* concentrations in oysters can exceed 10,000 cells per gram of oyster meat during  
74 warmer, summer months [13], and high numbers of *V. vulnificus* can be found in warm estuarine waters,  
75 including those in the Northern Gulf of Mexico, incidence of *V. vulnificus* illnesses as a result of raw  
76 oyster consumption or wound infections [14] are relatively rare compared with levels that might be  
77 expected if all *V. vulnificus* strains were virulent. As a result of public health concerns, researchers have

78 developed numerous methods with the goal of distinguishing between clinical (virulent) and  
79 environmental strains (presumed to be less virulent) [15].

80 An early study using terminal restriction fragment length polymorphisms (T-RFLP) by Nilsson et al.  
81 (2003) [16] described a link between two variations in the 16S rRNA region of *V. vulnificus* and the  
82 clinical or environmental origin of strains. Later modified by Vickery et al. (2007) [17] as a real-time PCR  
83 assay, isolates identified as Type A were found to be associated with environmentally-collected strains,  
84 type B isolates were consistent with those of clinical origin, and type AB (positive for both type A and B),  
85 a mix of clinical and environmental. Frequently used to characterize the pathogenicity of  
86 environmentally collected samples [18, 19], the 16S rRNA method has been used as a standard in some  
87 method comparison studies [20]. As an alternative to molecular-based detection, Drake et al. (2010)  
88 [20] reported a positive correlation between the fermentation of D-mannitol and 16S rRNA type B  
89 isolates, suggesting its application as a simple screening tool for virulence potential. Most recently, an  
90 assay was reported utilizing a polymorphism in the *pilF* gene of *V. vulnificus* to identify clinical strains  
91 [21, 22]. Since *pilF* encodes a protein necessary for the assembly of a Type IV Pilus, an essential  
92 virulence factor in many Gram negative bacteria, early studies suggest that detection of the *pilF*  
93 polymorphism could serve as a marker for human pathogenic strains of *V. vulnificus* [23]. Based upon  
94 Roig et al's study (2010) [22], another group of researchers, Baker-Austin et al. (2012) [21], developed a  
95 real-time PCR assay, utilizing *pilF*, to differentiate strains capable of causing infections in humans from  
96 non-pathogenic strains in different matrices.

97

98 An additional method of distinguishing pathogenic potential is the virulence correlated gene (*vcgC/vcgE*)  
99 assay, which has been reported to differentiate between virulent and non-virulent strains of *V. vulnificus*  
100 in a manner similar to the 16S rRNA assay discussed above. Application of the *vcg* gene model has  
101 demonstrated a strong discriminatory capability of clinical vs environmental in biotype I strains [24, 25].

102 Research indicates that two primary lineages may exist within biotype I strains; one, the *vcgC* allele and  
103 the other, *vcgE* [26, 27]. While both may express virulence in murine models, *vcgC* positive strains are  
104 more likely to be associated with systemic infection and mortality [27]. Recent research suggests that  
105 some C type strains of environmental origin (not recovered from human patients) demonstrate growth  
106 inhibition by human serum [28], and many E type strains have shown virulence in iron dextran treated  
107 mouse models [27]. Thus, the *vcgC/vcgE* assay is particularly useful in identifying strains more likely to  
108 be associated with clinical cases than not.

109 The goal of this study was to characterize clinical and environmental strains of *V. vulnificus* isolated from  
110 sources in the Gulf of Mexico and Southeast U.S. using one phenotypic and three genotypic methods.  
111 We examined 252 previously collected clinical and environmental isolates using the 16S rRNA gene  
112 assay, the *pilF* gene assay, the *vcgC/vcgE* assay, and D-mannitol fermentation to compare the virulence  
113 potential of each isolate, as well as the agreement between the 16S rRNA method and the three other  
114 techniques.

115

## 116 **2. MATERIALS AND METHODS**

### 117 2.1 Bacterial Strains

118 A total of 252 previously-isolated strains of *V. vulnificus* were used in this study. Environmental strains  
119 (n=171) were collected between 2005 and 2012 from oysters, sediment, or water samples in Florida,  
120 Texas, Louisiana, or South Carolina, and clinical strains (n=81) were provided by the Texas Department  
121 of Health Lab (n=28), the U.S. Food and Drug Administration (n=32), the Florida Department of Health  
122 (n=19), and the Alabama Department of Health (n=2).

123

124 Environmental strains from FL, TX, LA, and the 2005 SC strains were isolated on *Vibrio vulnificus* Agar  
125 (VVA) and confirmed as *V. vulnificus* using colony blot hybridization with an alkaline phosphatase  
126 labeled DNA probe targeting the species-specific *vvhA* gene in *V. vulnificus* (VVAP) [29-32]. Positive  
127 (*Vibrio vulnificus* ATCC 27562) and negative (*Vibrio parahaemolyticus* ATCC 17802) controls were used.  
128 After color development, colonies that hybridized with the probe were purple-brown in color. The limit  
129 of detection is 10 CFU/g oyster, sediment or mL of water. The 2012 SC environmental isolates were  
130 collected from sites along the Waccamaw River and in three shellfish growing water areas in Winyah  
131 Bay, and plated onto CPC+ and CHROMagar Vibrio (CAV) plates. DNA was extracted from individual *V.*  
132 *vulnificus* isolates using the Qiagen DNeasy protocol and stored at -80°C. A TaqMan based real-time PCR  
133 assay targeting the hemolysin A gene (*vvhA*) [33] was used to confirm the *V. vulnificus* isolates. *V.*  
134 *vulnificus* strains M-06 and Env1, were provided by Rachel Noble (University of North Carolina, Institute  
135 of Marine Sciences) and used as positive and negative controls for clinical and environmental strains,  
136 respectively in the 16S rRNA, and *pilF* real-time PCR assays and the D-mannitol fermentation test. All  
137 strains were maintained at -80°C in tryptic soy broth with 2.5% NaCl and 20% (vol/vol) glycerol.

## 138 2.2 Bacterial Growth and DNA isolation

139 Bacterial strains were grown from frozen stocks on Tryptic Soy Agar (TSA) with 2.5% NaCl at 35°C for 24  
140 hours prior to DNA extraction or D-mannitol inoculation. Bias was minimized during sample analyses by  
141 numerically coding individual strains. Strains were analyzed and typed without the knowledge of strain  
142 origin. For DNA extractions, a loopful (~1µL) of cells was added to a 1.5 mL micro-centrifuge tube of  
143 phosphate buffered saline (PBS) [7.65 g NaCl, 0.724 g anhydrous Na<sub>2</sub>HPO<sub>4</sub>, 0.21 g KH<sub>2</sub>PO<sub>4</sub> L<sup>-1</sup> of D.I.  
144 water, pH 7.4] (APHA 1970) [34] and extracted using the DNeasy Blood and Tissue kit following the  
145 manufacturer protocol for bacterial cells (Qiagen). Recovered DNA was checked for purity by  
146 spectrophotometry using a Nanodrop ND-1000 spectrophotometer (Thermo Scientific). Extractions

147 showing very low DNA readings were discarded, and the procedure was repeated beginning with the  
148 frozen stock cultures. D-mannitol tubes were inoculated directly with a loop (~1µL) of cells from the TSA  
149 with 2.5% NaCl plates.

### 150 2.3 16S rRNA Assay

151 The characterizations of each isolate as type A (environmental), type B (clinical) or type AB was  
152 performed using the previously described qPCR protocol (Vickery et al. 2007) [17] on an iQ5  
153 thermocycler (BioRad). Small modifications were made to the procedure to reflect a difference in  
154 premade reagents. Each 25µl reaction contained: 12.5µl of 2X BioRad iQ Supermix, 2µl of 25µM MgCl,  
155 0.5 µl of 10µM forward primer (Vvu16S51-F; **Table 1**), 0.5 µl of 10 µM reverse primer (Vvu16S221-R),  
156 0.1875 µl of 10µM Type A probe (Vvu16SA-P), 0.1875 µl of 10µM Type B probe (Vvu16SB-P), 7.125 µl of  
157 nuclease-free water, and 2µl of extracted DNA. Cycle conditions were consistent with those reported in  
158 Vickery et al. (2007) [17].

### 159 2.4 *vcgC/vcgE* Polymorphism Assay

160 A species specific primer/probe combination was employed for the PCR detection of the C type allele of  
161 the virulence correlated gene (*vcgC*) [35]. Primers and probes are shown in **Table 1**. The mastermix was  
162 comprised of 1 µM PCR Buffer, 2.5 µM MgCl, 0.2 µM DNTP's, 0.25 µM forward and reverse primers, 0.18  
163 µM probe, 0.3 µM Qiagen Top Taq (Qiagen, Venlo, Limburg), and water to volume for 25µL reactions  
164 using 3 µL template DNA. Amplification and product detection were performed on a Bio Rad CFX 96  
165 Real Time PCR System under the following conditions: Initial denaturation at 95°C for 180 s, followed by  
166 45 cycles of denaturation at 95°C for 15 s and combined annealing and extension at 60° C for 90 s.  
167 Primer pairs previously published [36, 37] were used for PCR detection of the Environmental type (E)  
168 allele of the virulence correlated gene (*vcg*). Primers and probes are shown in **Table 1**. The mastermix

169 was comprised of 12.5  $\mu$ L Sso Fast Evagreen<sup>®</sup> Supermix (Bio-Rad Laboratories, Inc., Hercules, CA), 0.3  
170  $\mu$ M of each primer, and water to volume for 25 $\mu$ L reactions using 5 $\mu$ L template DNA. Amplification and  
171 product detection was performed on a Bio-Rad CFX 96 Real Time PCR System under the following  
172 conditions: a 3 minute initial denaturation at 94 $^{\circ}$  C, followed by 40 cycles of 94 $^{\circ}$ C for 45 seconds, 55 $^{\circ}$ C  
173 for 45 seconds, and 72 $^{\circ}$  C for 45 seconds. Products were visualized in real time using the SYBR green  
174 channel and evaluated post-hoc using melt curve analysis.

#### 175 2.5 *pilF* Polymorphism Assay

176 Amplification of the *pilF* polymorphism was performed by modifying a previously described method  
177 [21]. Optimal results were achieved on an iQ5 thermocycler (BioRad) using 2x iQ5 Supermix and by  
178 reducing the primer and probe (**Table 1**) to a final concentration of 0.1 $\mu$ M.

#### 179 2.6 D-mannitol Fermentation

180 All isolates were tested for the ability to ferment the carbohydrate D-mannitol. Actively growing cells of  
181 each isolate were transferred to a culture tube containing 5mL of D-mannitol fermentation broth with  
182 phenol red. Inoculated tubes were incubated at 35 $^{\circ}$ C for 48 hours and each strain was evaluated for the  
183 ability to ferment D-mannitol as indicated by a color change from a neutral red to an acidic yellow. For  
184 each set of samples, a positive and negative control, and an un-inoculated blank were used for color  
185 comparison.

#### 186 2.7 Data Analysis

187 Each isolate was identified as positive or negative for the *pilF* gene and ability to ferment D-mannitol,  
188 and typed as C or E by the *vcg* assay and as A, B, or AB using the 16S rRNA method (also called the *rrn*  
189 system by several researchers) (**Tables 2, 3**). While isolates of clinical origin (blood or other samples  
190 from infected patient) can be assumed with reasonable confidence to be virulent, all that is known of



191 those of environmental origin is that they were collected from water/sediment/oysters. The presence of  
192 the *pilF* gene, *vcgC*, ability to ferment D-mannitol and B typing have all been suggested as characteristics  
193 of clinical strains.

194 Classification of isolates identified as 16S rRNA type AB is generally considered ambiguous; therefore all  
195 strains identified as such (n=20; **Tables 2, 3**) were excluded from the analyses of the 16S rRNA assay.  
196 Additionally 15 environmental isolates that could not be typed as *vcg C* or *E* were omitted from the  
197 calculations which included this assay.

198 The ability of each assay to correctly characterize isolates as clinical or environmental in origin was  
199 assessed by calculating: a) the positive predictive value (PPV) for clinical isolates (proportion of isolates  
200 that tested as *vcgC*, D-mannitol fermentation positive, 16S rRNA type B or *pilF* positive that were of  
201 clinical origin); b) the negative predictive value (NPV) (proportion of isolates that were *vcgE*, D-mannitol  
202 fermentation negative, 16S rRNA type A or *pilF* negative that were of environmental origin); c) the  
203 sensitivity (proportion of clinical isolates correctly identified by each test [38] (- *vcgC*, D-mannitol  
204 positive, 16S rRNA type B or *pilF* positive); d) specificity (proportion of environmental isolates that were  
205 correctly identified as *vcgE*, D-mannitol negative, 16S rRNA type A or *pilF* negative) [37], [38]; and e) the  
206 overall percent agreement of each assay for all isolates (all correctly predicted isolates, both  
207 environmental and clinical, divided by total number of isolates). All values were calculated using  
208 Fisher's Exact Test and significance of results was assessed at the  $p$ -value < 0.05 level.

209 While the pathogenicity of all clinical isolates is presumed known, the pathogenicity of the  
210 environmentally collected strains is not clear. For this reason, we also calculated agreement between  
211 the D-mannitol, *vcg* and *pilF* individual tests with the 16S rRNA assay.

212 Finally, Pearson's correlation coefficients for each assay and source were calculated to determine the  
213 strength of the relationships between assays and between each assay and origin.

214 **3.0 RESULTS**

215 Our study examined 252 *V. vulnificus* isolates, 171 collected from environmental sources (water,  
216 sediment, or oyster samples), and 81 recovered from infected patients, here described as ‘clinical’  
217 (**Tables 2 and 3**).

218 The results of each of the four assays (16S rRNA gene, the *vcg C* and *E* alleles, the *pilF* gene, and the  
219 ability to ferment D-mannitol) for all isolates are shown in **Tables 2 and 3**.

220 The 16S rRNA method, developed by Vickery et al. (2007) [17], uses a polymorphism in the 16S rRNA  
221 gene to type isolates into A (environmental), B (clinical) or AB (having characteristics of both). Twenty  
222 of the 252 isolates tested were identified as type AB (7.9%) in the present study, and these were  
223 excluded from any comparative analysis that included the 16S rRNA results. Of the 81 clinical isolates,  
224 four were characterized as type AB (4.9%), while 75.3% were type B and 19.8% were type A.

225 Distribution of the 171 environmental isolates was 9.4% AB, 20.5% B and 70.1% A. Thus, 19.8 % of the  
226 clinical isolates typed as environmental isolates, and 20.5% of the environmental isolates typed as  
227 clinical isolates with the 16S rRNA marker.

228 The *vcgC/vcgE* assay utilizes sequence variations in the virulence correlated gene as a means of  
229 differentiating source and potential virulence. For our isolates 74.1% of the clinical group had the *vcgC*  
230 sequence, 25.9% *vcgE*. For environmental isolates the proportions were 75.4% with *vcgE*, 15.8% *vcgC*,  
231 and neither variant could be detected in 8.8% of the strains. For the *vcgC/vcgE* marker, 25.9 % of the  
232 clinical isolates typed as environmental isolates, and 15.8% of the environmental strains typed as clinical  
233 ones.

234 The *pilF* method differentiates between clinical and environmental isolates through the positive  
235 amplification of a polymorphism in the *pilF* gene frequently present in clinical isolates [21, 22]. A

236 negative result in the *pilF* test, no amplification, is associated with an isolate of environmental origin. Of  
237 our clinical isolates 76.5% were *pilF* positive, while 81.9% of the environmental isolates were *pilF*  
238 negative, and only 18.1% were positive for *pilF*. Overall, for the *pilF* assay, 23.5% of the clinical strains  
239 were negative (typed as environmental strains), and 18.1 % of the environmental isolates were positive  
240 (typed as clinical strains).

241 The final method examined the ability of a *V. vulnificus* isolate to ferment the carbohydrate, D-mannitol.  
242 A positive D-mannitol test has been associated with clinical isolates [20] and a negative result with  
243 environmental source isolates. While 77.8% of the clinical isolates were able to ferment D-mannitol,  
244 almost 40% of the environmental isolates were also D-mannitol fermentation positive.

245 Predictive values, sensitivity and specificity [38] were examined for each of the assays to evaluate their  
246 potential use in differentiating clinical from environmental *V. vulnificus* isolates using the characteristics  
247 positive for *pilF*, ability to ferment D-mannitol, *vcgC* and type B as 'virulence' characteristics. Results are  
248 summarized in **Table 4**. Positive predictive values (PPV; **Table 4**) i.e. proportion of isolates that tested  
249 positive (clinical) that were clinical, for each method ranged between 63.5 and 68.9% for the *pilF*, *vcg*  
250 and 16S rRNA assays; the ability to ferment D-mannitol had a significantly lower positive predictive value  
251 (48.8%) ( $p < 0.05$ ), due to a large number of environmental isolates that tested positive for this assay, i.e.  
252 were false positives. Negative predictive values (NPV) were all greater than 85%; i.e. over 85% of  
253 isolates testing *pilF* negative, *vcgE*, type A or D-mannitol negative were from environmental sources.

254 The proportion of clinical isolates that were identified as such by each assay (sensitivity) were similar for  
255 all the assays, ranging from 74% (*vcgC*) to 79% (type B), showing each method was able to identify  
256 approximately three quarters of the clinical isolates as clinical. However, when comparing specificity, the  
257 proportion of environmental isolates that were identified as such (16S rRNA type A, *pilF* negative, *vcgE*  
258 or did not ferment D-mannitol) was significantly higher for *pilF* and *vcg* assays (~82%). D-mannitol

259 fermentation (61.4%) was significantly inferior ( $p < 0.01$ ) to each of the other methods for specificity, as  
260 the result of the large number of environmental isolates (66 of 171) incorrectly identified as clinical in  
261 origin (i.e. D-mannitol fermentation positive).

262 Overall percentage agreement for all isolates was high, and similar, for the three molecular assays (78.0-  
263 80.2%) but was significantly lower for D-mannitol fermentation (66.7%). Many of the environmental  
264 isolates tested D-mannitol positive (38.5%) i.e. there were many false positives for clinical origin isolates.

265 The overall percent agreement (both positives and negatives) between each test and the 16S rRNA assay  
266 were high – for mannitol fermentation 78.9% (183/232), *pilF* 85.3% (198/232) and for *vcg* 95.4%  
267 (207/217).

268 Pearson's correlation coefficients between each assay and between each assay and isolate source  
269 showed moderate to strong relationships and all were highly significant ( $p < 0.001$ ). D-mannitol  
270 fermentation and source had the weakest relationship ( $r = 0.3661$ ) with D-mannitol and *pilF* also having a  
271 weaker relationship ( $r = 0.4013$ ). *Vcg* type and 16S rRNA were strongly correlated ( $r = 0.89$ ) while *pilF* and  
272 D-mannitol were also correlated with 16S rRNA ( $r = 0.6960$  and  $0.6057$  respectively).

273

#### 274 **4.0 DISCUSSION**

275 Public health concerns over *V. vulnificus* outbreaks have motivated the development of multiple  
276 procedures aimed at rapidly and effectively identifying potentially pathogenic strains [20]. Although  
277 numerous systems have been reported, none has proven to be accurate in all cases. Previous studies  
278 have demonstrated the ability of methods utilizing polymorphisms of the 16S rRNA gene, the *vcg C* and  
279 *E* alleles, the *pilF* gene, and the ability to ferment D-mannitol, as ways to distinguish between clinical  
280 and environmental strains of *V. vulnificus*. The focus of our study was the validation of these four

281 methods using a large collection of previously isolated *V. vulnificus* strains of both clinical and  
282 environmental origin.

283 The application of the 16S rRNA gene for *V. vulnificus* clinical/environmental discrimination has been  
284 used historically in comparative studies and environmental detection applications [15, 18, 19, 27, 39,  
285 40]. Vickery et al. (2007) [17] found that type B isolates were associated with 76% of the clinical strains  
286 tested. Our examination provided similar results, with 61/81 (75.3%) of clinical isolates identified as  
287 type B. Vickery et al. (2007) [17] also found that 20/23 (87.0%) of non-clinical strains, not identified as  
288 type AB, were type A. Again, we found fairly similar results, 77.4% of environmental isolates not  
289 identified as AB were identified as type A. Vickery et al. (2007) [17] determined that 22% of 86 *V.*  
290 *vulnificus* strains tested in their study originally appeared as type A, but when reanalyzed, were type 16S  
291 rRNA type AB.

292 A study by Nigro et al. (2011) [41] examined *V. vulnificus* in Lake Pontchartrain water after Hurricanes  
293 Katrina and Rita (2005-2006) and found 80% of the isolates were type A and 20% were type B. Gordon et  
294 al. (2008) [42] identified 30% of oyster isolates and 40% of water isolates as type B in a Florida study.  
295 The *vcgC/E* assay has been used in several studies to distinguish clinical from environmental strains.  
296 Jones et al. (2013) [39] found 32% (153/471) of isolates were *rrnB/vcgC* and 61% (289/471) were  
297 *rrnA/vcgE* or *rrnAB/vcgE*. In Jones et al. (2013) [39] study, six isolates were untypeable by the *rrn*  
298 system (16s rRNA) and four isolates were untypeable by the *vcg* system, while in the present study, 15  
299 *V. vulnificus* isolates were untypeable by the *vcg* method but all isolates could be typed with the 16S  
300 rRNA system (now being called the *rrn* system by some researchers). Arias et al. (2010) [43] had 11  
301 isolates that were untypeable by the *rrn* system. Previous studies report that the *vcg* type corresponds  
302 closely with source: *vcgC* type corresponds 90% to clinical isolation and the *vcgE* type corresponds 93%  
303 to environmental isolation [28, 36]. According to Warner and Oliver (2007) [44] estuarine water

304 samples contain almost equal percentages of *C*-type and *E*-type cells, while oysters contain 13% *C*-type  
305 and 87% *E*-type cells. In this study only 18 oyster isolates were included and of these 17 were *vcgE* type.  
306 Overall, three quarters of our 171 environmental isolates were *vcgE* type, and conversely 74% of the  
307 clinical isolates were *vcgC*, suggesting that this assay has some discriminatory value. However, the fact  
308 that 26% of clinical isolates (from infected patients) were *vcgE* type, clearly demonstrates the difficulty  
309 in differentiating clinical strains of this species. A study by Kim and Cho (2015) [45] using BOX-PCR,  
310 isolated 52 unique genotypes in *V. vulnificus* leading them to conclude that genotype assays may not be  
311 reliable for either virulence or isolate source.

312 Although the *pilF* assay has only been subjected to limited testing, Roig et al. (2010) [22] found that  
313 unlike other genotypic methods, the *pilF* polymorphism appears to be present in human-pathogenic  
314 strains of all three biotypes. Although we only tested this with isolates collected from the Gulf and  
315 Southeastern U.S. , the *pilF* polymorphism was detected by Roig et al. (2010) [22] utilizing isolates  
316 collected from the U.S., Europe, Asia and Australia. Challenging the classification ability of the *pilF*  
317 polymorphism against isolates confirmed to be pathogenic (resistant to human serum), the real-time  
318 PCR assay developed and tested by Baker-Austin et al. (2012) [21] correctly identified 91% (16/17) of *V.*  
319 *vulnificus* biotype 1. Only 76.5% (62/81) of clinical isolates were correctly identified, using the *pilF* assay  
320 by itself in our study, although overall percentage agreement, i.e. clinical isolates *pilF* (+), environmental  
321 *pilF* (-), was 80.2%. Roig et al. (2018) [46] identified five new lineages within 80 separate *V. vulnificus*  
322 strains that were different from the three standard biotypes. Two other papers suggest the difference  
323 between virulent and avirulent *V. vulnificus* strains may be either a strain's ability to colonize and  
324 survive in a human host or the host's susceptibility [46] rather than which virulence genes are  
325 present/not present [48].

326 D-mannitol fermentation was first reported as an effective means of categorizing isolates by Drake et al.  
327 (2010) [20]. In their study of 469 *V. vulnificus* isolates collected from oyster and water samples in the  
328 Gulf of Mexico, 91% of those identified as type B were also positive for D-mannitol fermentation. Bier et  
329 al. (2013) [49] identified positive mannitol fermentation in 15 of 19 (79%) of isolates from clinical cases,  
330 but in only 5 of 28 (18%) of environmental isolates. Our results were similar to those of Bier et al. (2013)  
331 [49] for clinical isolates - approximately 77.8% were able to ferment D-mannitol (sensitivity); however  
332 we found a much higher proportion of environmental isolates were D-mannitol fermentation positive  
333 (38.5%) (specificity). The mannitol phenotypic method was the same between the current study and  
334 Bier's 2013 assay. Differences in results between the two studies may be attributed to differences in the  
335 specific environmental sources (water, sediment, oysters) or specific locations. Bier et al. (2015) [50]  
336 developed and validated a multiplex PCR assay for the detection of 5 potential virulence genes in *V.*  
337 *vulnificus*: 16S rRNA type B allele, *vcgC* allele, the *nanA* gene, pathogenicity region XII and the mannitol  
338 *manIIA* gene. They could detect the *nanA* gene and the *vcgC* allele with a sensitivity and specificity of  
339 100% [50].

340 Froelich and Oliver (2011) [28] found that *vcgC* strains can be further separated into 2 subtypes (based  
341 upon isolate source and whether the individual strain could ferment mannitol or not). These  
342 researchers stated that all mannitol positive *Vibrio vulnificus* strains contain the 3 genes of the mannitol  
343 fermentation operon located next to each other. However, if the gene-spanning fragment is missing,  
344 the strain was mannitol negative [28]. As 16S rRNA identification has been widely applied, the  
345 agreement between the individual tests and the A/B designation was calculated and found to be  
346 relatively high, especially for the *vcgC/E* assay, where agreement was 95.4%. Agreement with the ability  
347 to ferment D-mannitol was significantly less, at 78.9%.

348 As noted earlier, the type AB identified isolates (7.9% of 252 isolates) were removed from the analyses  
349 which included the 16S rRNA assay due to uncertainty in classification. Sixteen out of 20 originated from  
350 environmental sources (**Table 3**). However, as 67.9% (171/252) of our isolates were of environmental  
351 origin, if 20 type AB designations were selected randomly from our 252 isolates, statistically 13.6 of  
352 those 20 would be associated with environmentally collected isolates. Therefore our study provides no  
353 additional insight into the relationship between type AB isolates and source. Also of note, all four of the  
354 type AB clinical isolates in our study were identified as negative by the *pilF* and D-mannitol assays, and  
355 six of the 18 *V. vulnificus* strains isolated from oyster samples (33%) were identified as type AB, a much  
356 higher percentage than the expected 6.0% (14/234) ratio of all other strains in our collection not  
357 isolated from oysters. This increased prevalence of type AB in oysters has been observed in studies  
358 conducted in Alabama [19], Louisiana [20, 51], and New Zealand [40]. Gordon et al. (2008) [42] also  
359 found a substantial proportion of oyster isolates from restricted waters (19.4%) were 16S rRNA type AB.  
360 In a study of *V. vulnificus* isolates collected from the dorsal fin of fishes in the Gulf of Mexico, Tao et al.  
361 (2012) [18] identified 9% of isolates as type AB. Givens et al. (2014) [52] examined *V. vulnificus* in fish  
362 intestines, oysters, sediment and water and determined that overall 60% of 123 isolates were type A,  
363 7.3% were type B, 32% were type AB, and 0.8% were untypeable.

364 Classifying strains of environmental origin only on the source of collection may not indicate an avirulent  
365 strain. Thiaville et al. (2011) [27] reported virulent strains of the E genotype. Bier et al. (2013) [49]  
366 reported clinical E genotypes from wound infections in the Baltic. Roig et al. (2010) [22] found several  
367 environmentally collected isolates that were resistant to human serum, and thus would be categorized  
368 as pathogenic. The evidence Roig et al. (2018) [46] found in their later lineage study supports their  
369 theory that all *V. vulnificus*, regardless of biotype, origin, or year collected, can infect humans. Reynaud  
370 et al (2013) [26] stated “No available molecular markers with sufficient resolving power to categorize  
371 with absolute certainty the pathogenicity of *V. vulnificus* strains” (from [53]). Baker-Austin and Oliver



372 (2018) [47] also stated that no single virulence gene correlates with observed virulence. Several studies  
373 utilizing the 16S rRNA assay have found type B isolates in non-clinical samples. Wood and Arias (2012)  
374 [19], noted that more than 50% (n=154) of 294 isolates collected from oysters in coastal Alabama, were  
375 type B, although it is unknown how many of these isolates would be considered pathogenic. Tao et al.  
376 (2012) [18] observed that 72 of 244 *V. vulnificus* isolates collected from the surfaces of fish were type B  
377 (29%), 22 were type AB (9%), and 157 were type A (62%). In 10 samples collected from Pacific oysters in  
378 New Zealand, Kirs et al. (2011) [40] found an 8:1:1 ratio of Type A:B:AB. Again, questions remain as to  
379 how many of these environmentally collected type B isolates are potentially pathogenic to humans.  
380 Conversely, Gordon et al. (2008) [42] detected approximately equal numbers of type A and B in a  
381 collection of clinical strains from Florida and suggested a geographical variation in *V. vulnificus*  
382 populations and further calling into question the effectiveness of the 16S rRNA assay when used as the  
383 sole method of strain characterization. As many of our clinical isolates were provided by the Florida  
384 Department of Health, we would like to note that 16 of the 19 isolates collected in Florida in 2012 were  
385 identified as 16S rRNA type B (**Table 3**), suggesting a possible anomaly in the previous data. Only two of  
386 the five 1994-1996 Florida-collected clinical strains in our collection were found to be type B, which is far  
387 too small of a sample to draw any conclusions about Florida isolates. In addition, the isolates examined  
388 in this study are limited to the Southeast U.S., and thus unable to address geographical variation in *V.*  
389 *vulnificus* populations.

390

391 Overall this study contributes to the literature on distinguishing between clinical and environmental  
392 *Vibrio vulnificus* isolates of known origin, using several assays currently being investigated to clarify  
393 virulence mechanisms in this pathogen. Based on our set of 252 *V. vulnificus* isolates, collected in the  
394 Gulf of Mexico and Southeast U.S., we can recommend not using the phenotypic D-mannitol

395 fermentation test as the sole means of identifying virulent strains. The *vcgC/E* typing and the *pilF* assay  
396 are each similar in classification ability to the 16S rRNA method, suggesting they are valid alternatives..  
397 In addition, an advantage of using *pilF* is that it provides a dichotomous classification, removing  
398 ambiguous identifications such as the 16S rRNA type AB, or isolates that are *vcg* untypeable. The story  
399 of virulence in *V. vulnificus* is continuously evolving. Recent advances using Whole Genome Sequencing  
400 and other ‘omics’ based approaches [54, 55] are rapidly expanding our knowledge of this opportunistic  
401 pathogen.

402

#### 403 **ACKNOWLEDGMENTS**

404 The authors are grateful to the following State Health Laboratories who provided clinical *V. vulnificus*  
405 isolates to us: (1) Florida—Beth Burden, Ron Baker, Bob Vincent with the Florida Department of Health,  
406 Bureau of Laboratories; (2) Alabama—Pat Morrow, Joanna Roberson with the Bureau of Clinical  
407 Laboratories, Alabama Department of Public Health; (3) Texas—Tamara Baldwin, Jim Borne with the  
408 Texas Department of State Health Services Laboratories; and (4) the U.S. Food and Drug Administration.  
409 The authors thank Katrina Mott, MHS, for assistance with statistical analysis. Funding for this study was  
410 provided by the National Oceanic and Atmospheric Administration through grant award  
411 #NA08NOS4730440 to the Florida Department of Environmental Protection, Tallahassee, Florida, in  
412 association with the Water Quality Priority Issue Team of the Gulf of Mexico Alliance (contract #  
413 WM992). Their support is gratefully acknowledged.

414

415 **Conflict of interest:** No conflict of interest declared.

416

417 **Literature Cited**

418 [1] N.A. Daniels, *Vibrio vulnificus* oysters: pearls and perils, *Clinical Infectious Diseases* 52(6) (2011) 788-  
419 792.

420

421 [2] M. Iwamoto, T. Ayers, B.E. Mahon, D.L. Swerdlow, Epidemiology of seafood-associated infections in  
422 the United States, *Clinical microbiology reviews* 23(2) (2010) 399-411.

423

424 [3] CDC, National Enteric Disease Surveillance: COVIS Annual Summary.,  
425 [http://www.cdc.gov/national-surveillance/PDFs/CSTE\\_Vibrio2009.pdf](http://www.cdc.gov/national-surveillance/PDFs/CSTE_Vibrio2009.pdf) (2011).

426

427 [4] M.A. Horseman, S. Surani, A comprehensive review of *Vibrio vulnificus*: an important cause of severe  
428 sepsis and skin and soft-tissue infection, *International Journal of Infectious Diseases* 15(3) (2011) e157-  
429 e166.

430

431 [5] M. Raissy, H. Momtaz, M. Moumeni, M. Ansari, E. Rahimi, Molecular detection of *Vibrio* spp. in  
432 lobster hemolymph, *African Journal of Microbiology Research* 5(13) (2011) 1697-1700.

433

434 [6] J. Martinez-Urtaza, J.C. Bowers, J. Trinanes, A. DePaola, Climate anomalies and the increasing risk of  
435 *Vibrio parahaemolyticus* and *Vibrio vulnificus* illnesses, *Food Research International* 43(7) (2010) 1780-  
436 1790.

437

438 [7] C.S. Pfeffer, M.F. Hite, J.D. Oliver, Ecology of *Vibrio vulnificus* in estuarine waters of eastern North  
439 Carolina, *Applied and Environmental Microbiology* 69(6) (2003) 3526-3531.

440

441 [8] R. Shapiro, S. Altekruise, L. Hutwagner, R. Bishop, R. Hammond, S. Wilson, B. Ray, S. Thompson, R.  
442 Tauxe, P. Griffin, The role of Gulf Coast oysters harvested in warmer months in *Vibrio vulnificus*  
443 infections in the United States, 1988–1996, *Journal of Infectious Diseases* 178(3) (1998) 752-759.  
444

445 [9] CDC, Foodborne Diseases Active Surveillance Network (FoodNet): FoodNet Surveillance Report for  
446 2011 (Final Report). Atlanta, Georgia; US Dept of Health and Human Services, CDC. (2012).  
447

448 [10] A. Newton, M. Kendall, D.J. Vugia, O.L. Henao, B.E. Mahon, Increasing rates of vibriosis in the United  
449 States, 1996–2010: review of surveillance data from 2 systems, *Clinical Infectious Diseases* 54 (suppl\_5)  
450 (2012) S391-S395.  
451

452 [11] C. Baker-Austin, J. Trinanes, N. Gonzalez-Escalona, J. Martinez-Urtaza, Non-cholera vibrios: the  
453 microbial barometer of climate change, *Trends in microbiology* 25(1) (2017) 76-84.  
454

455 [12] L. Vezzulli, I. Brettar, E. Pezzati, P.C. Reid, R.R. Colwell, M.G. Höfle, C. Pruzzo, Long-term effects of  
456 ocean warming on the prokaryotic community: evidence from the vibrios, *The ISME journal* 6(1) (2012)  
457 21-30.  
458

459 [13] M. Motes, A. DePaola, D. Cook, J. Veazey, J. Hunsucker, W. Garthright, R. Blodgett, S. Chirtel,  
460 Influence of water temperature and salinity on *Vibrio vulnificus* in northern gulf and atlantic coast  
461 oysters (*Crassostrea virginica*), *Applied and environmental microbiology* 64(4) (1998) 1459-1465.  
462

463 [14] C.N. Johnson, A.R. Flowers, N. Noriega, A. Zimmerman, J.C. Bowers, A. DePaola, D.J. Grimes,  
464 Relationships between environmental factors and pathogenic vibrios in the northern Gulf of Mexico,  
465 Applied and environmental microbiology 76(21) (2010) 7076-7084.  
466

467 [15] E. Sanjuán, B. Fouz, J.D. Oliver, C. Amaro, Evaluation of genotypic and phenotypic methods to  
468 distinguish clinical from environmental *Vibrio vulnificus* strains, Applied and environmental microbiology  
469 75(6) (2009) 1604-1613.  
470

471 [16] W.B. Nilsson, R.N. Paranjypte, A. DePaola, M.S. Strom, Sequence polymorphism of the 16S rRNA  
472 gene of *Vibrio vulnificus* is a possible indicator of strain virulence, Journal of clinical microbiology 41(1)  
473 (2003) 442-446.  
474

475 [17] M.C. Vickery, W.B. Nilsson, M.S. Strom, J.L. Nordstrom, A. DePaola, A real-time PCR assay for the  
476 rapid determination of 16S rRNA genotype in *Vibrio vulnificus*, Journal of Microbiological Methods 68(2)  
477 (2007) 376-384.  
478

479 [18] Z. Tao, A.M. Larsen, S.A. Bullard, A.C. Wright, C.R. Arias, Prevalence and population structure of  
480 *Vibrio vulnificus* on fishes from the northern Gulf of Mexico, Applied and environmental microbiology  
481 78(21) (2012) 7611-7618.  
482

483 [19] R. Wood, C. Arias, Distribution and survival of *Vibrio vulnificus* genotypes in postharvest Gulf Coast  
484 (USA) oysters under refrigeration, Journal of applied microbiology 113(1) (2012) 172-180.  
485

486 [20] S.L. Drake, B. Whitney, J.F. Levine, A. DePaola, L.-A. Jaykus, Correlation of mannitol fermentation  
487 with virulence-associated genotypic characteristics in *Vibrio vulnificus* isolates from oysters and water  
488 samples in the Gulf of Mexico, *Foodborne Pathogens and Disease* 7(1) (2010) 97-101.  
489

490 [21] C. Baker-Austin, E. Lemm, R. Hartnell, J. Lowther, R. Onley, C. Amaro, J.D. Oliver, D. Lees, *pilF*  
491 polymorphism-based real-time PCR to distinguish *Vibrio vulnificus* strains of human health relevance,  
492 *Food microbiology* 30(1) (2012) 17-23.  
493

494 [22] F.J. Roig, E. Sanjuán, A. Llorens, C. Amaro, *pilF* polymorphism-based PCR to distinguish *Vibrio*  
495 *vulnificus* strains potentially dangerous to public health, *Applied and environmental microbiology* 76(5)  
496 (2010) 1328-1333.  
497

498 [23] S. Chakraborty, M. Monfett, T.M. Maier, J.L. Benach, D.W. Frank, D.G. Thanassi, Type IV pili in  
499 *Francisella tularensis*: roles of *pilF* and *pilT* in fiber assembly, host cell adherence, and virulence,  
500 *Infection and immunity* 76(7) (2008) 2852-2861.  
501

502 [24] T.M. Rosche, E.A. Binder, J.D. Oliver, *Vibrio vulnificus* genome suggests two distinct ecotypes,  
503 *Environmental Microbiology Reports* 2(1) (2010) 128-132.  
504

505 [25] E. Warner, J.D. Oliver, Population structures of two genotypes of *Vibrio vulnificus* in oysters  
506 (*Crassostrea virginica*) and seawater, *Applied and Environmental Microbiology* 74(1) (2008) 80-85.  
507

508 [26] Y. Reynaud, S. Pitchford, S. De Decker, G.H. Wikfors, C.L. Brown, Molecular typing of environmental  
509 and clinical strains of *Vibrio vulnificus* isolated in the northeastern USA, *PLoS One* 8(12) (2013) e83357.

510

511 [27] P.C. Thiaville, K.L. Bourdage, A.C. Wright, M. Farrell-Evans, C.W. Garvan, P.A. Gulig, Genotype is  
512 correlated with but does not predict virulence of *Vibrio vulnificus* biotype 1 in subcutaneously  
513 inoculated, iron dextran-treated mice, *Infection and Immunity* 79(3) (2011) 1194-1207.

514

515 [28] B. Froelich, J. Oliver, Orientation of mannitol related genes can further differentiate strains of *Vibrio*  
516 *vulnificus* possessing the *vcgC* allele, *Adv. Stud. Biol* 3 (2011) 151-160.

517

518 [29] A. DePaola, M.L. Motes, D.W. Cook, J. Veazey, W.E. Garthright, R. Blodgett, Evaluation of an alkaline  
519 phosphatase-labeled DNA probe for enumeration of *Vibrio vulnificus* in Gulf Coast oysters, *Journal of*  
520 *microbiological methods* 29(2) (1997) 115-120.

521

522 [30] C.A. Kaysner, A. DePaola, *Vibrio cholerae*, *V. parahaemolyticus*, *V. vulnificus*, and other *Vibrio* spp.,  
523 in: USFDA (Ed.), *Food and Drug Administration Bacteriological Analytical Manual Online*: 8th edn,  
524 Revision A, 1998. Chapter 9. Substantially rewritten and revised May 2004.  
525 [http://www.cfsan.fda.gov/\\_ebam/bam-9.html](http://www.cfsan.fda.gov/_ebam/bam-9.html)2004.

526 [31] S. McCarthy, A. DePaola, D. Cook, C. Kaysner, W. Hill, Evaluation of alkaline phosphatase-and  
527 digoxigenin-labelled probes for detection of the thermolabile hemolysin (*tlh*) gene of *Vibrio*  
528 *parahaemolyticus*, *Letters in applied microbiology* 28(1) (1999) 66-70.

529

530 [32] A.C. Wright, G.A. Miceli, W.L. Landry, J. Christy, W. Watkins, J. Morris, Rapid identification of *Vibrio*  
531 *vulnificus* on nonselective media with an alkaline phosphatase-labeled oligonucleotide probe, *Applied*  
532 *and Environmental Microbiology* 59(2) (1993) 541-546.

533

534 [33] G. Panicker, A.K. Bej, Real-time PCR detection of *Vibrio vulnificus* in oysters: comparison of  
535 oligonucleotide primers and probes targeting *vvhA*, Applied and environmental microbiology 71(10)  
536 (2005) 5702-5709.  
537

538 [34] American Public Health Association (APHA). 1970. Recommended procedures for the examination  
539 of seawater and shellfish, 4<sup>th</sup> ed. (1970) American Public Health Association. Washington, D.C.  
540

541 [35] C. Baker-Austin, A. Gore, J.D. Oliver, R. Rangdale, J.V. McArthur, D.N. Lees, Rapid in situ detection of  
542 virulent *Vibrio vulnificus* strains in raw oyster matrices using real-time PCR, Environmental Microbiology  
543 Reports 2(1) (2010) 76-80.  
544

545 [36] T.M. Rosche, Y. Yano, J.D. Oliver, A rapid and simple PCR analysis indicates there are two subgroups  
546 of *Vibrio vulnificus* which correlate with clinical or environmental isolation, Microbiology and  
547 Immunology 49(4) (2005) 381-389.  
548

549 [37] E.B. Warner, J.D. Oliver, Multiplex PCR assay for detection and simultaneous differentiation of  
550 genotypes of *Vibrio vulnificus* biotype 1, Foodborne pathogens and disease 5(5) (2008) 691-693.  
551

552 [38] D.G. Altman, J.M. Bland, Diagnostic tests. 1: Sensitivity and specificity, BMJ: British Medical Journal  
553 308 (6943) (1994) 1552.  
554

555 [39] J.L. Jones, C.H. Lüdeke, J.C. Bowers, A. DePaola, Comparison of plating media for recovery of total  
556 and virulent genotypes of *Vibrio vulnificus* in US market oysters, International journal of food  
557 microbiology 167(3) (2013) 322-327.



558 [40] M. Kirs, A. Depaola, R. Fyfe, J. Jones, J. Krantz, A. Van Laanen, D. Cotton, M. Castle, A survey of  
559 oysters (*Crassostrea gigas*) in New Zealand for *Vibrio parahaemolyticus* and *Vibrio vulnificus*,  
560 International journal of food microbiology 147(2) (2011) 149-153.  
561

562 [41] O.D. Nigro, A. Hou, G. Vithanage, R.S. Fujioka, G.F. Steward, Temporal and spatial variability in  
563 culturable pathogenic *Vibrio* spp. in lake Pontchartrain, Louisiana, following Hurricanes Katrina and Rita,  
564 Applied and environmental microbiology 77(15) (2011) 5384-5393.  
565

566 [42] K.V. Gordon, M.C. Vickery, A. DePaola, C. Staley, V.J. Harwood, Real-time PCR assays for  
567 quantification and differentiation of *Vibrio vulnificus* strains in oysters and water, Applied and  
568 environmental microbiology 74(6) (2008) 1704-1709.  
569

570 [43] C.R. Arias, O. Olivares-Fuster, J. Goris, High intragenomic heterogeneity of 16S rRNA genes in a  
571 subset of *Vibrio vulnificus* strains from the western Mediterranean coast, Int Microbiol 13 (2010) 179-  
572 188.  
573

574 [44] E. Warner, J.D. Oliver, Refined medium for direct isolation of *Vibrio vulnificus* from oyster tissue and  
575 seawater, Applied and environmental microbiology 73(9) (2007) 3098-3100.  
576

577 [45] H.-J. Kim, J.-C. Cho, Genotypic diversity and population structure of *Vibrio vulnificus* strains isolated  
578 in Taiwan and Korea as determined by multilocus sequence typing, PloS One 10(11) (2015) e0142657.  
579

580 [46] F.J. Roig, F. González-Candelas, E. Sanjuán, B. Fouz, E.J. Feil, C. Llorens, C. Baker-Austin, J.D. Oliver,  
581 Y. Danin-Poleg, C.J. Gibas, Phylogeny of *Vibrio vulnificus* from the analysis of the core-genome:  
582 implications for intra-species taxonomy, *Frontiers in microbiology* 8 (2018) 2613.  
583

584 [47] C. Baker-Austin, J.D. Oliver, *Vibrio vulnificus*: new insights into a deadly opportunistic pathogen,  
585 *Environmental microbiology* 20(2) (2018) 423-430.  
586

587 [48] K.E. Phillips, K.J. Satchell, *Vibrio vulnificus*: from oyster colonist to human pathogen, *PLoS pathogens*  
588 13(1) (2017) e1006053.  
589

590 [49] N. Bier, S. Bechlars, S. Diescher, F. Klein, G. Hauk, O. Duty, E. Strauch, R. Dieckmann, Genotypic  
591 diversity and virulence characteristics of clinical and environmental *Vibrio vulnificus* isolates from the  
592 Baltic Sea region, *Applied and environmental microbiology* 79(12) (2013) 3570-3581.  
593

594 [50] N. Bier, S. Diescher, E. Strauch, Multiplex PCR for detection of virulence markers of *Vibrio vulnificus*,  
595 *Letters in Applied Microbiology* 60( 5) (2015) 414-420.  
596

597 [51] F. Han, S. Pu, A. Hou, B. Ge, Characterization of clinical and environmental types of *Vibrio vulnificus*  
598 isolates from Louisiana oysters, *Foodborne pathogens and disease* 6(10) (2009) 1251-1258.  
599

600 [52] C. Givens, J. Bowers, A. DePaola, J. Hollibaugh, J. Jones, Occurrence and distribution of *Vibrio*  
601 *vulnificus* and *Vibrio parahaemolyticus*: potential roles for fish, oyster, sediment and water, *Letters in*  
602 *applied microbiology* 58(6) (2014) 503-510.  
603

604 [53] S. Elmahdi, S. Parveen, S. Ossai, L.V. DaSilva, M. Jahncke, J. Bowers, J. Jacobs, *Vibrio*  
605 *parahaemolyticus* and *Vibrio vulnificus* recovered from oysters during an oyster relay study, *Applied and*  
606 *environmental microbiology* 84(3) (2018).

607

608 [54] S.R. Church, T. Lux, C. Baker-Austin, S. Buddington, S. Michelle, *Vibrio vulnificus* type 6 secretion  
609 system 1 contains anti-bacterial properties, *PLOS ONE* 11(10): e0165500.  
610 <https://doi.org/10.1371/journal.pone.0165500> (2016)

611

612 [55] A. Guerrero, A.F. Licea-Navarro, R. González-Sánchez, M.L. Lizárraga-Partida, Whole-genome  
613 comparison between reference sequences and oyster *Vibrio vulnificus* C-genotype strains, *PLOS ONE*  
614 14(7): e0220385. <https://doi.org/10.1371/journal.pone.0220385> (2019).

615

616

617

618

619

620

621

622

623

624 **Table 1** Primers, probes and oligonucleotides used in the study to characterize *Vibrio vulnificus* isolates

Primer, Probe, or Oligonucleotide	Sequence	Reference
Vvu16S51-F	5'-CAAGTCGAGCGGCAGCA-3'	Vickery et al. 2007
Vvu16S221-R	5'-TCCTGACGCGAGAGAGGCC-3'	Vickery et al. 2007
Vvu16SA-P	5'-6FAM-TGATAGCTTCGGCTCAA-MGBNFQ -3'	Vickery et al. 2007
Vvu16SB-P	5'-TET-CCCGTAGGCATCATGC-MGBNFQ -3'	Vickery et al. 2007
PilF F	5'-GATTGACTACGAYCCACACCG-3'	Baker-Austin et al. 2012
PilF R	5'-GRCGCGCTTGGGTGTAG-3'	Baker-Austin et al. 2012
PilF Probe	5'-FAM-TGCTCAACCTCGCTAAGTTGGAAATCGATAC-TAMRA-3'	Baker-Austin et al. 2012
vcgC-F	5'-AAAACCTCATTGARCAGTAACGAAA-3'	Baker-Austin et al. 2010
vcgC-R	5'AGCTGGATCTAAKCCCAATGC-3'	Baker-Austin et al. 2010
vcgC-P	5'/TAMRA/AATTAAGCCGTCAAGCCACTTGACTGTAAAGAA/FAM/- 3'	Baker-Austin et al. 2010
vcgE-F	5'-CTCAGAAAGGCTCAATTGAC-3'	Warner and Oliver 2008b
vcgE-R	5'-GATTAACGCTGTAAGGCCG-3'	Warner and Oliver 2008b

625

626

627

628

629

630

631

632

633

634

635 **Table 2** Summary of characteristics of environmental *Vibrio vulnificus* isolates from Alabama (AL), Florida  
 636 (FL), Louisiana (LA), Maryland (MD), Mississippi (MS), Oregon (OR), Rhode Island (RI), South Carolina (SC)  
 637 or Texas (TX).

# of Isolates	States	Matrix	Years	<i>vcgC/vcgE</i>	16S rRNA	<i>pilF</i>	Mannitol
22	TX	Water	2006, 2007	E	A	-	-
6	TX	Water	2006, 2007	E	A	-	+
2	TX	Water	2007	E	A	+	-
3	TX	Water	2006, 2007	C	B	-	+
6	TX	Water	2006, 2007	C	B	+	+
33	SC	Water	2005, 2012	E	A	-	-
15	SC	Water	2005, 2012	E	A	-	+
2	SC	Water	2005, 2012	E	A	+	-
2	SC	Water	2005, 2012	E	B	-	-
1	SC	Water	2012	E	B	-	+
5	SC	Water	2005, 2012	C	A	-	+
1	SC	Water	2005	C	A	+	+
1	SC	Water	2012	C	B	-	-
2	SC	Water	2012	C	B	-	+
4	SC	Water	2005, 2012	C	B	+	+
12	SC	Sediment	2005, 2012	E	A	-	-
8	SC	Sediment	2005, 2012	E	A	-	+
1	SC	Sediment	2005	C	A	-	-
1	SC	Sediment	2012	C	B	-	+
1	SC	Sediment	2012	C	B	+	-
1	SC	Sediment	2005	C	B	+	+
7	TX, LA, FL, MS, OR, RI	Oyster	1998, 1999	E	A	-	-
3	TX, FL	Oyster	1999	E	A	-	+
2	LA	Oyster	1998, 1999	E	A	+	-
Vv <i>vcgC/vcgE</i> untyp strains							
5	SC	Water	2012	Untyp	B	-	+
5	SC	Water	2012	Untyp	B	+	-
1	SC	Water	2012	Untyp	B	+	+
1	SC	Sediment	2012	Untyp	A	+	-
2	SC	Sediment	2012	Untyp	B	-	+

1	SC	Water	2005	Untyp	AB	+	-
Vv 16S rRNA type AB strains							
4	TX, SC	Water	2007, 2012	E	AB	-	-
1	SC	Water	2012	E	AB	-	+
2	TX, SC	Water	2007, 2012	E	AB	+	-
4	LA, MD	Oyster	1998	E	AB	-	-
1	LA	Oyster	1998	E	AB	+	-
1	TX	Oyster	1999	C	AB	+	+
2	SC	Sediment	2012	E	AB	-	-

638

639

640

641

642

643

644

645

646 **Table 3.** Summary of characteristics of clinical *Vibrio vulnificus*, isolates from Alabama (AL), Florida (FL),  
647 Louisiana (LA) or Texas (TX).

# of Isolates	States	Years	16S rRNA	<i>pilF</i>	Mannitol	<i>vcgC/vcgE</i>
10	TX, LA, FL	1995, 1997, 2008, 2012	A	-	-	E
1	TX	2009	A	-	+	E
4	TX, LA, FL	1996, 2009, 2012	A	+	-	E
1	FL	1996	A	+	+	E
4	TX	2012	B	-	+	C
56	TX, LA, AL, FL	1994, 1995, 1996, 1996, 2008, 2009, 2012	B	+	+	C
1	LA	1995	B	+	+	E
4	TX, LA/FL	1994, 1995, 2008	AB	-	-	E

648

649

650

651

652 **Table 4.** Predictive values, sensitivity and specificity of each assay for clinical and environmental *Vibrio*  
 653 *vulnificus* isolates.

654

655	16S RNA	D-mannitol	<i>pilF</i>	<i>vcg</i>	
656	B/A	fermentation +/-	+/-	C/E	
657					
658	PPV*	63.5% (61/96)	48.8% (63/129)	66.7% (62/93)	68.9% (60/87)
659					
660	NPV†	88.2% (120/136)	85.4% (105/123)	88.1% (140/159)	86.0% (129/150)
661					
662	Sensitivity	79.2% (61/77)	77.8% (63/81)	76.5% (62/81)	74.1% (60/81)
663					
664	Specificity	77.4% (120/155)	61.4% (105/171)	81.9% (140/171)	82.7% (129/156)
665					
666	Overall agreement	78.0% (181/232)	66.7% (168/252)	80.2% (202/252)	79.8% (189/237)

667 \*PPV=Positive Predictive Value; † NPV=Negative Predictive Value

668  
 669  
 670